Methods and devices for detection and acquisition of biomarkers

Patent metadata

Field	Value
Publication number	US-9540684-B2
Application number	US-201314106661-A
Country	US
Kind code	B2
Filing date	Dec 13, 2013
Priority date	Dec 14, 2012
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream).

First claim

What is claimed is:

1. A method for detecting one or more biomarkers from a tissue or biological sample of a subject, comprising:
(a) providing a device comprising one or more microneedles to which one or more probes specific for the one or more biomarkers are covalently attached, wherein the one or more probes comprise polynucleotides complementary to the one or more biomarkers;
(b) contacting the microneedle device with the tissue or biological sample of the subject such that the one or more probes complementary to the one or more biomarkers hybridize to the one or more biomarkers in situ, thereby binding the one or more biomarkers to the one or more microneedles; and
(c) detecting the one or more biomarkers that are bound to the one or more probes on the one or more microneedle, wherein at least one biomarker is an mRNA polynucleotide and wherein the one or more biomarkers bound to the one or more probes on the one or more microneedles are present in quantities amenable to detection following elution from the one or more microneedles, and wherein the method is able to detect mRNA biomarkers present in the tissue or biological sample at a concentration of 1.66 pM.

2. The method of claim 1 , wherein the device comprises a plurality of probes complementary to a plurality of different biomarkers, and wherein each probe of the plurality of probes is attached to a different microneedle.

3. The method of claim 1 , wherein the device comprises a plurality of probes complementary to an identical biomarker, and wherein the plurality of probes complementary to the identical biomarker are attached to two or more microneedles.

4. The method of claim 1 , wherein the one or more biomarkers complementary to the one or more probes on the microneedles are detected by conducting a polymerase chain reaction (PCR).

5. The method of claim 4 , wherein the PCR is real-time PCR.

6. The method of claim 4 , wherein the one or more biomarkers complementary to the one or more probes comprise a DNA biomarker and the method further comprises detecting the DNA biomarker.

7. The method of claim 1 , wherein the one or more microneedles comprise polycarbonate, and the one or more probes are attached to the one or more microneedles via a thiol/amino bifunctional linker.

8. The method of claim 1 , wherein at least one of the polynucleotides complementary to the one or more biomarkers hybridizes to a polymorphism in the biomarker.

9. The method of claim 1 , wherein the one or more probes are DNA polynucleotides.

10. The method of claim 1 , wherein the tissue or biological sample is derived from a human.

11. The method of claim 1 , wherein the tissue or biological sample is skin.

12. The method of claim 11 , wherein at least one of the one or more biomarkers is associated with a skin cancer.

13. The method of claim 12 , wherein the skin cancer is melanoma.

14. The method of claim 12 , wherein the skin cancer is a non-melanocyte skin cancer.

15. The method of claim 11 , wherein at least one of the one or more biomarkers is a biomarker associated with an autoimmune disease.

16. The method of claim 15 , wherein the autoimmune disease is psoriasis.

17. The method of claim 11 , wherein at least one of the one or more biomarkers is associated with an infectious disease.

18. The method of claim 1 , wherein one or more of the microneedles are made of a polymer.

19. The method of claim 1 , wherein the detecting the one or more biomarkers comprises conducting a quantitative assay.

20. The method of claim 1 , wherein the detecting the one or more biomarkers comprises conducting an amplification assay.

21. The method of claim 1 , wherein the detecting the one or more biomarkers comprises conducting a reverse-transcription assay.

22. The method of claim 1 , wherein the mRNA polynucleotide is released from cells disrupted by the one or more microneedles.

23. The method of claim 1 , wherein the polynucleotides complementary to the one or more biomarkers are between 15 and 100 nucleotides in length.

24. The method of claim 1 , wherein the biomarkers bound to the one or more probes are present at a level detectable following dilution of the biomarkers.

25. The method of claim 2 , wherein the plurality of probes are identical probes.

Assignees

• Mindera Corp
• Scripps Research Inst

Inventors

• Mahmood Tahir A
• Dickerson Tobin J
• Mahmood Nadir A
• Capek Petr

Classifications

• C12Q1/6837 Primary

  using probe arrays or probe chips (C12Q1/6874 takes precedence) · CPC title

• C12Q1/6841 Primary

  In situ hybridisation · CPC title

• A61K9/0021

  Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title

• A61B5/150015

  Source of blood · CPC title

• A61B5/685

  Microneedles · CPC title